Dexamethasone dex

OVA (CAS NO. 9006-59-1, Biotechnology grade), montelukast (CAS NO.151767-02-1, LC&T, purity ≥ 98%) and 18β-GA(CAS NO. 471-53-4, purity ≥ 98%) were obtained from Macklin Biochemical Co., Ltd. (Shanghai, China). Dexamethasone (DEX, purity ≥ 99%) was purchased from Beyotime Biotechnology Company Ltd. (Shanghai, China). NCI-H292 cell (the human lung epithelial cell line) was purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China).

The CRL‐12424 cells were inoculated in 12‐well plates at a density of 1 × 10⁴ cells cm⁻². In the case of conditioned media treatment, cells were cultured with the mixture of osteoclast media collected after osteoclastogenesis induction with/without rapamycin treatment for 5 days and basic α‐MEM medium (1:2 v/v ratio), with basic α‐MEM medium was used as the negative control. In case of the influence of rapamycin on osteogenesis of MSCs, CRL‐12424 cells were cultured with osteogenic medium [basic α‐MEM medium containing 10 mmβ‐glycerophosphate (β‐GP) (Beyotime, China), 1.0 × 10⁻⁸ m dexamethasone (Dex) (Beyotime, China), and 50 µg mL⁻¹ vitamin C (VitC) (Beyotime, China) plus/minus rapamycin (0.17 µm). The medium was changed every other day. Samples were collected after 7 days to evaluate osteogenic differentiation of CRL‐12424 cells.